12:00 AM
 | 
Jan 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tolenix: Phase II data

Top-line data from a double-blind, crossover, international Phase II trial in 138 patients showed that twice-daily Tolenix (2 mg tolterodine plus 9 mg pilocarpine) met the co-primary endpoints of reducing urination frequency and the number of incontinence episodes per day vs. placebo. Tolenix also met the secondary endpoint of improving saliva production and dry mouth side effects...

Read the full 264 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >